Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint

Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc. (NYSE: MRK), known as MSD outside the United States
and Canada, today announced that the pivotal Phase 3 clinical study of
letermovir, an investigational antiviral medicine, met its primary
endpoint.Language:
EnglishContact: MerckMedia:Pam Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more

Source: Merck.com - Corporate News - October 19, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Letermovir MSD NYSE:MRK Source Type: news